BioVie Inc. (BIVI): Price and Financial Metrics
GET POWR RATINGS... FREE!
BIVI Stock Price Chart Interactive Chart >
BIVI Price/Volume Stats
| Current price | $2.64 | 52-week high | $19.10 |
| Prev. close | $2.54 | 52-week low | $2.50 |
| Day low | $2.55 | Volume | 20,400 |
| Day high | $2.70 | Avg. volume | 44,247 |
| 50-day MA | $3.78 | Dividend yield | N/A |
| 200-day MA | $5.03 | Market Cap | 65.96M |
BioVie Inc. (BIVI) Company Bio
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. It develops BIV201, which completed Phase 2a clinical trial for the treatment of ascites due to chronic liver cirrhosis. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was founded in 2013 and is based in Santa Monica, California.
Latest BIVI News From Around the Web
Below are the latest news stories about Biovie Inc that investors may wish to consider to help them evaluate BIVI as an investment opportunity.
BioVie begins treatment in phase 2 trial of NE3107 for Parkinson''s diseaseBioVie (BIVI) treated the first patient in a phase 2 trial assessing the potential pro-motoric impact of NE3107 in patients with Parkinsons disease |
BioVie Announces Treatment of First Patient in Phase 2 Clinical Trial of NE3107 for the Treatment of Parkinson’s DiseaseRENO, Nev., Jan. 20, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders today announced the treatment of the first patient in the Company’s Phase 2 clinical trial assessing the potential pro-motoric impact of its NE3107 asset in Parkinson’s disease patients. The NM201 study (NCT05083260) is a double-blind, placebo |
Has Biocept, Inc. (BIOC) Outpaced Other Medical Stocks This Year?Here is how Biocept, Inc. (BIOC) and BioVie Inc. (BIVI) have performed compared to their sector so far this year. |
BioVie to Participate at the LifeSci Partners 11th Annual Corporate Access EventRENO, Nev., Dec. 28, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today announced the participation of its management team in a panel and in one-on-one investor meetings at the LifeSci Partners 11th Annual Corporate Access Event, to be held virtually January 5-7, 2022. Details on the panel can be found bel |
BioVie Announces Partnership with the American Liver FoundationCampaign to Improve Education on Ascites Due to Liver Cirrhosis and Raise Awareness of BioVies Phase 2b Study of BIV201 for Refractory Ascites Campaign to Improve Education on Ascites Due to Liver Cirrhosis and Raise Awareness of BioVies Phase 2b Study of BIV201 for Refractory Ascites |
BIVI Price Returns
| 1-mo | -31.43% |
| 3-mo | -19.51% |
| 6-mo | -60.00% |
| 1-year | -80.80% |
| 3-year | -78.88% |
| 5-year | -91.13% |
| YTD | -41.33% |
| 2021 | -74.02% |
| 2020 | 394.86% |
| 2019 | N/A |
| 2018 | 0.00% |
| 2017 | -49.15% |
Loading social stream, please wait...